Clinical trials: Drug Interaction
Interaction Drug Food
Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
Kratom is a botanical natural product that has opioid-like effects. Kratom is commonly used to self-treat withdrawal symptoms associated with opioid addiction, as well as pain.
- Trial name
- NCT04392011
- Testing
- Midazolam HCl, Dextromethorphan HBr, Kratom
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Washington State University
Drug Interactions
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
- Trial name
- NCT06717100
- Testing
- Nintedanib 150 MG [Ofev]
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PureTech
Healthy, PK Drug-drug Interaction Study
Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension
This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are…
- Trial name
- NCT06585163
- Testing
- Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Quivive Pharma, Inc.
Drug Interaction Study
Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117
This Study evaluates the Effect of St. John's Wort dry Extract Ze 117 on Several Cytochrome P450 Enzymes and on Transporter P-Glycoprotein in Healthy Volunteers.
- Trial name
- NCT03482817
- Testing
- Ze 117, Probe drug cocktail
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Max Zeller Soehne AG
Drug-drug Interaction Study
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
The goal of this clinical study was to determine the effect of the test drug ceftobiprole (a drug approved for the treatment of bacterial infections) on the elimination of pitavastatin (a drug approved for the treatment of…
- Trial name
- NCT06808646
- Testing
- pitavastatin, pitavastatin single dose combined with ceftobiprole
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Drug Interaction
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
The purpose of this study was to investigate how vamorolone affects the CYP3A4 enzyme in humans by measuring the pharmacokinetics of midazolam and its metabolite, 1'-hydroxymidazolam, in healthy subjects.
- Trial name
- NCT06689527
- Testing
- Vamorolone, Midazolam
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Santhera Pharmaceuticals
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
HIV Infections, Contraception
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
The study investigators are conducting an observational, parallel group pharmacokinetic (PK) study among women living with HIV (WLHIV) already on 1st line antiretroviral therapy (ART) and virally suppressed, 18-45 years old…
- Conditions
- HIV Infections, Contraception, Drug-drug Interaction
- Trial name
- EPIC (NCT04669678)
- Testing
- Etonogestrel (ETG) implant, Intramuscular depo-medroxyprogesterone acetate (IM DMPA), Sub-cutaneous medroxyprogesterone acetate (SC MPA)
- Where
- South Africa
- Volunteers
- 110 people
- Sponsor
- University of Alabama at Birmingham
Drug-Drug Interaction, HIV Infection
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART)…
- Trial name
- DPART (NCT04487145)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- 2 sites in Uganda
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Drug Drug Interaction
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
Primary objective: To evaluate the plasma and urine PK of Givinostat following multiple oral doses of Givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of Givinostat.
- Trial name
- NCT05860114
- Testing
- Givinostat
- Where
- Portugal
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Drug-Drug Interaction, Heathy Volunteer
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Primary objective: 1. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose pharmacokinetics (PK) of intravenous or oral midazolam. 2.
- Trial name
- NCT05492318
- Testing
- Givinostat 10 mg/mL, Midazolam 1mg/ml IV, Midazolam 2.5 mg oromucosal solution
- Where
- Portugal
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Safety Issues, Pharmacokinetics
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
This is a phase I, open-label, fixed sequence design, drug-drug-interaction (DDI) study divided in 2 parts. Part I is designed to evaluate whether concomitant treatment with linaprazan glurate and clarithromycin, a strong…
- Conditions
- Safety Issues, Pharmacokinetics, Drug Interaction, Tolerability
- Trial name
- NCT05633147
- Testing
- Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2)
- Where
- Sweden
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Drug Interaction
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
This is a single-centre, open-label, fixed-sequence trial to evaluate the impact of C21 on the exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp substrates in healthy volunteers.
- Trial name
- NCT05830799
- Testing
- Drug Drug Interaction
- Where
- Sweden
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade.
- Trial name
- NCT05081583
- Testing
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington State University
Drug Interaction, Analgesics
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
- Conditions
- Drug Interaction, Analgesics, Opioid Use Disorder
- Trial name
- NCT04818086
- Testing
- Lemborexant, Buprenorphine-naloxone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Drug Drug Interaction
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
Primary objective: To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of Givinostat…
- Trial name
- NCT05845567
- Testing
- Givinostat, Clarithromycin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Drug Interaction
Cannabidiol and CES1 Interactions in Healthy Subjects
The proposed study will assess the drug interaction potential between oral cannabidiol (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12 healthy research subjects
- Trial name
- NCT04603391
- Testing
- dl-Methylphenidate plus Cannabidiol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Florida
Drug-Interactions
Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole…
- Trial name
- NCT04201197
- Testing
- Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Drug Drug Interaction
Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)
An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects…
- Trial name
- NCT03909529
- Testing
- Digoxin 250 MCG Oral Tablet, Spironolactone 25 mg/ 5 mL S/F Suspension
- Where
- India
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- CMP Development, LLC
Pharmacokinetics, Safety
JOTROL PK, Safety, and Food Effect Assessment
Type of Study: Single Ascending Doses (SAD) Study Objectives: To characterize the pharmacokinetic (PK) profile of JOTROL (resveratrol) following oral administration of SAD ranging from 200 mg up to a dose currently estimated at…
- Conditions
- Pharmacokinetics, Safety, Food-drug Interaction
- Trial name
- NCT04668274
- Testing
- 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jupiter Orphan Therapeutics Inc.